Your browser doesn't support javascript.
loading
ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
Groenendijk, Floris H; de Jong, Jeroen; Fransen van de Putte, Elisabeth E; Michaut, Magali; Schlicker, Andreas; Peters, Dennis; Velds, Arno; Nieuwland, Marja; van den Heuvel, Michel M; Kerkhoven, Ron M; Wessels, Lodewijk F; Broeks, Annegien; van Rhijn, Bas W G; Bernards, René; van der Heijden, Michiel S.
Affiliation
  • Groenendijk FH; Division of Molecular Carcinogenesis, Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Jong J; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Fransen van de Putte EE; Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Michaut M; Division of Molecular Carcinogenesis, Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Schlicker A; Division of Molecular Carcinogenesis, Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Peters D; Core Facility for Molecular Pathology and Biobanking, Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Velds A; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Nieuwland M; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van den Heuvel MM; Division of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Kerkhoven RM; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Wessels LF; Division of Molecular Carcinogenesis, Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Broeks A; Core Facility for Molecular Pathology and Biobanking, Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Rhijn BW; Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Bernards R; Division of Molecular Carcinogenesis, Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van der Heijden MS; Division of Molecular Carcinogenesis, Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: ms.vd.heijden@nki.nl.
Eur Urol ; 69(3): 384-8, 2016 Mar.
Article in En | MEDLINE | ID: mdl-25636205
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Biomarkers, Tumor / Receptor, ErbB-2 / Neoadjuvant Therapy / Mutation, Missense Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur Urol Year: 2016 Document type: Article Affiliation country: Netherlands Country of publication: Switzerland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Biomarkers, Tumor / Receptor, ErbB-2 / Neoadjuvant Therapy / Mutation, Missense Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur Urol Year: 2016 Document type: Article Affiliation country: Netherlands Country of publication: Switzerland